|
|
Blood, 1 December 2003, Vol. 102, No. 12, pp. 4187-4190.
Prepublished online as a Blood First Edition Paper on August 7, 2003; DOI 10.1182/blood-2003-04-1150.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief report
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib
Kathryn Wilkinson,
Elvira R. P. Velloso,
Luiz Fernando Lopes,
Charles Lee,
Jon C. Aster,
Margaret A. Shipp, and
Ricardo C. T. Aguiar
From the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Hospital A.C. Camargo, São Paulo, Brazil; and Hospital das Clinicas, University of São Paulo, Brazil.
Eosinophilia is common in myeloproliferative disorders (MPDs) with abnormalities of chromosome band 5q31-33, including those that present with t(1;5)(q23;q33). With the development of rational drug therapy, characterization of the molecular targets for these translocations could guide treatment and affect patient survival. We cloned the t(1;5)(q23;q33) and showed that it fuses platelet-derived growth factor receptor beta (PDGFRB) to the coiled-coil domains of a novel partner protein, myomegalin. Using two-color interphase fluorescence in situ hybridization (FISH), we also demonstrated that the eosinophils are clonal in these disorders. Imatinib mesylate has recently been shown to be efficacious in MPDs with PDGFR activation. Therefore, following our molecular studies, we were able to redirect this patient's treatment. Although she had refractory and progressive disease, once imatinib was started, complete clinical and hematologic remission, as well as major cytogenetic response, was achieved. Given the therapeutic implications, our findings stress the need to aggressively investigate the molecular basis of these diseases, with emphasis on the PDGFR family. (Blood. 2003;102: 4187-4190)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. M. Vannucchi, P. Guglielmelli, and A. Tefferi
Advances in Understanding and Management of Myeloproliferative Neoplasms
CA Cancer J Clin,
May 1, 2009;
59(3):
171 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al.
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene
Haematologica,
February 1, 2007;
92(2):
163 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. David, N. C. P. Cross, S. Burgstaller, A. Chase, C. Curtis, R. Dang, M. Gardembas, J. M. Goldman, F. Grand, G. Hughes, et al.
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders
Blood,
January 1, 2007;
109(1):
61 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes
Biology of Platelet-Derived Growth Factor and Its Involvement in Disease
Mayo Clin. Proc.,
September 1, 2006;
81(9):
1241 - 1257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, M. A. Elliott, and A. Pardanani
Atypical Myeloproliferative Disorders: Diagnosis and Management
Mayo Clin. Proc.,
April 1, 2006;
81(4):
553 - 563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol.,
September 10, 2005;
23(26):
6285 - 6295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Delaval, S. Letard, H. Lelievre, V. Chevrier, L. Daviet, P. Dubreuil, and D. Birnbaum
Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome
Cancer Res.,
August 15, 2005;
65(16):
7231 - 7240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc.,
July 1, 2005;
80(7):
947 - 958.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Blood Eosinophilia: A New Paradigm in Disease Classification, Diagnosis, and Treatment
Mayo Clin. Proc.,
January 1, 2005;
80(1):
75 - 83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Blood,
January 1, 2005;
105(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. H. Grand, S. Burgstaller, T. Kuhr, E. J. Baxter, G. Webersinke, J. Thaler, A. J. Chase, and N. C. P. Cross
p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor {beta} in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder
Cancer Res.,
October 15, 2004;
64(20):
7216 - 7219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani and A. Tefferi
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
Blood,
October 1, 2004;
104(7):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Morerio, M. Acquila, C. Rosanda, A. Rapella, C. Dufour, F. Locatelli, E. Maserati, F. Pasquali, and C. Panarello
HCMOGT-1 Is a Novel Fusion Partner to PDGFRB in Juvenile Myelomonocytic Leukemia with t(5;17)(q33;p11.2)
Cancer Res.,
April 15, 2004;
64(8):
2649 - 2651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Vizmanos, F. J. Novo, J. P. Roman, E. J. Baxter, I. Lahortiga, M. J. Larrayoz, M. D. Odero, P. Giraldo, M. J. Calasanz, and N. C. P. Cross
NIN, a Gene Encoding a CEP110-Like Centrosomal Protein, Is Fused to PDGFRB in a Patient with a t(5;14)(q33;q24) and an Imatinib-Responsive Myeloproliferative Disorder1
Cancer Res.,
April 15, 2004;
64(8):
2673 - 2676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Gotlib, J. Cools, J. M. Malone III, S. L. Schrier, D. G. Gilliland, and S. E. Coutre
The FIP1L1-PDGFR{alpha} fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Blood,
April 15, 2004;
103(8):
2879 - 2891.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
